Drug-Target Information | ||||||||
---|---|---|---|---|---|---|---|---|
Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
sargramostim | gmcsfr-alpha | NA | Successful target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
47.74 | approved | unknown |
sargramostim | granulocyte-macrophage colony-stimulating factor receptor subunit alpha | biotech | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
47.74 | approved,investigational | agonist |
sargramostim | gmcsfr-alpha | NA | Successful target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
47.74 | approved | agonist |
sargramostim | cytokine receptor common subunit beta | biotech | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
47.74 | approved,investigational | agonist |
sargramostim | interleukin-3 receptor subunit alpha | biotech | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
sargramostim | bone marrow proteoglycan | biotech | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
sargramostim | syndecan-2 | biotech | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
click here to return to the previous page |